SPA
ITCI

Sherbrooke Park Advisers’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Sherbrooke Park Advisers’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-6,833
Closed -$468K – 1334
2024
Q2 		$468K Buy
6,833
+2,922
+75% +$203K 0.08% 443
2024
Q1 		$271K Buy
+3,911
New +$269K 0.05% 610

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sherbrooke Park Advisers's ITCI Position: Q3 2024 in Review

Sherbrooke Park Advisers sold out of Intra-Cellular Therapies Inc. (ITCI) in Q3 2024, closing a stake of 6,833 shares — an estimated $468K sold.

Sherbrooke Park Advisers first reported a position in ITCI in Q1 2024 and held it in 2 quarters. The position peaked at $468K in Q2 2024. 355 funds tracked by Wall St. Rank hold ITCI as of Q3 2024.

  • Sherbrooke Park Advisers reported no remaining Intra-Cellular Therapies Inc. position as of Q3 2024 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 6,833 Intra-Cellular Therapies Inc. shares in Q3 2024, an estimated $468K.
  • Sherbrooke Park Advisers first reported a position in Intra-Cellular Therapies Inc. in Q1 2024 and held it in 2 quarters.
  • Sherbrooke Park Advisers's Intra-Cellular Therapies Inc. position peaked at $468K in Q2 2024.
  • 355 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2024.

Based on Sherbrooke Park Advisers's 13F filing for Q3 2024, filed 14 Nov 2024.